RU2017107033A - Способы лечения депрессии с применением модуляторов nmda - Google Patents
Способы лечения депрессии с применением модуляторов nmda Download PDFInfo
- Publication number
- RU2017107033A RU2017107033A RU2017107033A RU2017107033A RU2017107033A RU 2017107033 A RU2017107033 A RU 2017107033A RU 2017107033 A RU2017107033 A RU 2017107033A RU 2017107033 A RU2017107033 A RU 2017107033A RU 2017107033 A RU2017107033 A RU 2017107033A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- depression
- weeks
- period
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 25
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 1
- 230000001430 anti-depressive effect Effects 0.000 claims 12
- 239000000935 antidepressant agent Substances 0.000 claims 12
- 229940005513 antidepressants Drugs 0.000 claims 12
- 238000011282 treatment Methods 0.000 claims 12
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims 11
- 230000006698 induction Effects 0.000 claims 10
- 208000020925 Bipolar disease Diseases 0.000 claims 6
- 208000024714 major depressive disease Diseases 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 238000011156 evaluation Methods 0.000 claims 3
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000009916 Postpartum depression Diseases 0.000 claims 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 208000025307 bipolar depression Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000037326 chronic stress Effects 0.000 claims 2
- 208000024732 dysthymic disease Diseases 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 208000012672 seasonal affective disease Diseases 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037374P | 2014-08-14 | 2014-08-14 | |
| US62/037,374 | 2014-08-14 | ||
| PCT/US2015/045071 WO2016025721A1 (en) | 2014-08-14 | 2015-08-13 | Methods of treating depression using nmda modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017107033A true RU2017107033A (ru) | 2018-09-14 |
| RU2017107033A3 RU2017107033A3 (enExample) | 2019-02-12 |
Family
ID=55304631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017107033A RU2017107033A (ru) | 2014-08-14 | 2015-08-13 | Способы лечения депрессии с применением модуляторов nmda |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20170296616A1 (enExample) |
| EP (1) | EP3180015A4 (enExample) |
| JP (2) | JP2017524721A (enExample) |
| KR (1) | KR20170040351A (enExample) |
| CN (1) | CN106659763A (enExample) |
| AU (2) | AU2015301650A1 (enExample) |
| BR (1) | BR112017002930A2 (enExample) |
| CA (1) | CA2957937A1 (enExample) |
| CL (1) | CL2017000378A1 (enExample) |
| CO (1) | CO2017002356A2 (enExample) |
| IL (1) | IL250557A0 (enExample) |
| MX (1) | MX2017002052A (enExample) |
| PH (1) | PH12017500275A1 (enExample) |
| RU (1) | RU2017107033A (enExample) |
| SG (2) | SG10201810016XA (enExample) |
| UA (1) | UA123623C2 (enExample) |
| WO (1) | WO2016025721A1 (enExample) |
| ZA (1) | ZA201701526B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180102052A (ko) * | 2015-10-16 | 2018-09-14 | 노오쓰웨스턴 유니버시티 | 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용 |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| US11358935B2 (en) | 2016-11-28 | 2022-06-14 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of lanicemine and their method of use |
| EP3706734A1 (en) * | 2017-11-10 | 2020-09-16 | Naurex Inc. | Methods of administration of nmda receptor agonists |
| US20200368310A1 (en) * | 2017-12-05 | 2020-11-26 | Naurex, INC | Treatment with nmda receptor modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| EP2485751B1 (en) * | 2009-10-05 | 2014-05-21 | Northwestern University | GLYX-13 for use in a method of treating refractory depression |
| US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
-
2015
- 2015-08-13 KR KR1020177006761A patent/KR20170040351A/ko not_active Ceased
- 2015-08-13 BR BR112017002930A patent/BR112017002930A2/pt not_active IP Right Cessation
- 2015-08-13 CN CN201580043626.3A patent/CN106659763A/zh active Pending
- 2015-08-13 WO PCT/US2015/045071 patent/WO2016025721A1/en not_active Ceased
- 2015-08-13 JP JP2017507973A patent/JP2017524721A/ja active Pending
- 2015-08-13 SG SG10201810016XA patent/SG10201810016XA/en unknown
- 2015-08-13 EP EP15832514.2A patent/EP3180015A4/en not_active Withdrawn
- 2015-08-13 CA CA2957937A patent/CA2957937A1/en not_active Abandoned
- 2015-08-13 US US15/503,840 patent/US20170296616A1/en not_active Abandoned
- 2015-08-13 AU AU2015301650A patent/AU2015301650A1/en not_active Abandoned
- 2015-08-13 RU RU2017107033A patent/RU2017107033A/ru not_active Application Discontinuation
- 2015-08-13 UA UAA201702145A patent/UA123623C2/uk unknown
- 2015-08-13 MX MX2017002052A patent/MX2017002052A/es unknown
- 2015-08-13 SG SG11201701134XA patent/SG11201701134XA/en unknown
-
2017
- 2017-02-12 IL IL250557A patent/IL250557A0/en unknown
- 2017-02-14 PH PH12017500275A patent/PH12017500275A1/en unknown
- 2017-02-14 CL CL2017000378A patent/CL2017000378A1/es unknown
- 2017-03-01 ZA ZA2017/01526A patent/ZA201701526B/en unknown
- 2017-03-10 CO CONC2017/0002356A patent/CO2017002356A2/es unknown
-
2020
- 2020-04-23 JP JP2020076468A patent/JP2020128391A/ja active Pending
- 2020-05-15 AU AU2020203165A patent/AU2020203165A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017002930A2 (pt) | 2017-12-05 |
| CL2017000378A1 (es) | 2017-11-03 |
| SG10201810016XA (en) | 2018-12-28 |
| MX2017002052A (es) | 2018-08-15 |
| EP3180015A4 (en) | 2018-02-14 |
| JP2020128391A (ja) | 2020-08-27 |
| IL250557A0 (en) | 2017-03-30 |
| CO2017002356A2 (es) | 2017-06-09 |
| AU2015301650A1 (en) | 2017-03-23 |
| PH12017500275A1 (en) | 2017-07-03 |
| ZA201701526B (en) | 2018-05-30 |
| EP3180015A1 (en) | 2017-06-21 |
| JP2017524721A (ja) | 2017-08-31 |
| UA123623C2 (uk) | 2021-05-05 |
| SG11201701134XA (en) | 2017-03-30 |
| RU2017107033A3 (enExample) | 2019-02-12 |
| KR20170040351A (ko) | 2017-04-12 |
| US20170296616A1 (en) | 2017-10-19 |
| CA2957937A1 (en) | 2016-02-18 |
| AU2020203165A1 (en) | 2020-06-04 |
| WO2016025721A1 (en) | 2016-02-18 |
| CN106659763A (zh) | 2017-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | New treatment strategies of depression: based on mechanisms related to neuroplasticity | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| FI3757126T3 (fi) | Menetelmä nivelreuman hoitamiseksi il-17-antagonistien avulla | |
| RU2019109464A (ru) | Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
| HRP20140784T1 (hr) | Glyx-13 za uporabu u postupku tretiranja refraktornih depresija | |
| RU2016149316A (ru) | Лечение ревматоидного артрита | |
| FI3744326T3 (fi) | Annosteluohjelma pitkävaikutteisten injektoitavien paliperidoniestereiden ottamatta jääneille annoksille | |
| JP2017524721A5 (enExample) | ||
| EA201890182A1 (ru) | Терапевтическое средство для лечения синдрома гунтера и способ его лечения | |
| HRP20201388T1 (hr) | Režimi i postupci liječenja multiple skleroze uporabom ofatumumaba | |
| MX2024013613A (es) | Anticuerpos il-13 para el tratamiento de la dermatitis atopica | |
| WO2017142871A8 (en) | Methods comprising fixed intermittent dosing of cediranib | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| Kim et al. | Effects of Electro and Laser Acupuncture Treatment with GB39 and GB34 on Neuropathic Pain in Rats Induced by Tibial and Sural Nerve Ligation※ | |
| EA202092978A3 (ru) | Фармацевтическая композиция для парентерального капельного введения | |
| NZ760033A (en) | Methods to treat opioid use disorder | |
| Bahk et al. | P. 3. c. 025 A randomised, double-blind, placebo-controlled 24-week trial of aripiprazole in recently remitted bipolar I patients | |
| Koenig et al. | What are effective nonopioid medications for treating chronic neck pain? | |
| McClure | Neuromodulation Treatments in Clinical Practice: Should TMS Be Used for the Treatment of Major Depressive Disorder? | |
| Zhang | Acupuncture and Herbal Medicine for Depression from Traditional Empiricism to Research Evidence | |
| Octavio et al. | P. 2.067 Long-term effects of aripiprazole on affective symptoms of schizophrenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210811 |